Eisai and Biogen announce Japan approval of LEQEMBI Pen
Eisai and Biogen said Japan approved “LEQEMBI Pen,” a subcutaneous formulation for early Alzheimer’s disease.
Story updates
06:01:46 AM UTC
SquawkNews
Biogen Inc. said Japan approved the subcutaneous LEQEMBI Pen for early Alzheimer’s, enabling once—weekly at—home dosing as an alternative to IV infusions. Eisai leads development and both companies co-commercialize.Material DetailsContext by AI AnalystThis extends LEQEMBI’s shift from clinic IV to…
Biogen said Japan has approved the subcutaneous LEQEMBI Pen for early Alzheimer’s disease, allowing once-weekly dosing at home as an alternative to IV infusions. Eisai leads development of the therapy, and Biogen and Eisai co-commercialize it.